Valor IV Pharma Holdings, LLC 4
4 · Harmony Biosciences Holdings, Inc. · Filed Aug 25, 2020
Insider Transaction Report
Form 4
Valor IV Pharma Holdings, LLC
10% Owner
Transactions
- Conversion
Common Stock
2020-08-21+240,668→ 13,166,357 total - Conversion
Common Stock
2020-08-21+12,080,352→ 12,925,688 total - Conversion
Series A Preferred Stock
2020-08-21−77,950,712→ 0 total→ Common Stock (12,080,352 underlying) - Conversion
Series C Preferred Stock
2020-08-21−1,810,126→ 0 total→ Common Stock (240,668 underlying)
Footnotes (4)
- [F1]Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering.
- [F2]Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein.
- [F3]Includes 2,950,712 shares received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020.
- [F4]Includes 23,141 shares received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020.